US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CITIUS ONCOLOGY INC

1.05

+0.08018.26%

Post-market: 1.050.00000.00%19:10 EDT

Volume:126.52K

Turnover:130.30K

Market Cap:75.14M

PE:-2.83

High:1.09

Open:0.9730

Low:0.9693

Close:0.9700

Loading ...

Overview Company News Filings

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025

THOMSON REUTERS

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Oncology to explore strategic alternatives

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live

Citius Oncology Retains Jeffries to Consider Strategic Alternatives

MT Newswires Live

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

THOMSON REUTERS

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate

BRIEF-Citius Oncology Reports Fiscal Full Year 2024 Financial Results And Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTOR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":1.0501,"timestamp":1749240000000,"preClose":0.97,"halted":0,"volume":126518,"hourTrading":{"tag":"盘后","latestPrice":1.0501,"preClose":1.0501,"latestTime":"19:10 EDT","volume":1269,"amount":1335.35,"timestamp":1749251414083},"delay":0,"floatShares":5502787,"shares":71552402,"eps":-0.371137,"marketStatus":"Market Closed","change":0.0801,"latestTime":"06-06 16:00:00 EDT","open":0.973,"high":1.09,"low":0.9693,"amount":130299.16755520001,"amplitude":0.124433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.371137,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.97,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":0.97,"latestTime":"08:29 EDT","volume":1753,"amount":1701.37863768,"timestamp":1749212985414},"postHourTrading":{"tag":"盘后","latestPrice":1.0501,"preClose":1.0501,"latestTime":"19:10 EDT","volume":1269,"amount":1335.35,"timestamp":1749251414083},"volumeRatio":4.336521011838304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":5502787,"roa":"-22.41%","roe":"-93.64%","lyrEps":-0.310765,"volumeRatio":4.336521011838304,"shares":71552402,"dividePrice":0,"high":1.09,"amplitude":0.124433,"preClose":0.97,"low":0.9693,"week52Low":0.5506,"pbRate":"2.11","week52High":49,"institutionHeld":0,"latestPrice":1.0501,"eps":-0.371137,"divideRate":0,"volume":126518,"delay":0,"ttmEps":-0.371137,"open":0.973,"prevYearClose":1.15,"prevWeekClose":0.9,"prevMonthClose":0.9,"prevQuarterClose":0.93,"fiveDayClose":0.9,"twentyDayClose":0.845,"sixtyDayClose":0.789},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501620986","title":"Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2501620986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501620986?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:15","pubTimestamp":1736255737,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the commercial la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-to-launch-lymphir-in-1h25?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-to-launch-lymphir-in-1h25?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOR","CTXR","BK4007","BK4139"],"gpt_icon":0},{"id":"2501664206","title":"Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501664206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501664206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:09","pubTimestamp":1736255380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O313O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","CTOR","CTXR"],"gpt_icon":0},{"id":"2501012832","title":"Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501012832","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501012832?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:08","pubTimestamp":1736255280,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology , today announced significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma . Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.\"Since LYMPHIR's approval in August 2024, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing, marketing, reimbursement and sales efforts. This is a pivotal inflection point as we transition from clinical development to revenue generation. Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including licensing partnerships in key international markets, f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4145","BK4139","BK4588","CTXR","MF","BK4526","BK4113","CTOR","CLS","BK4539","LU2045819591.USD","LU2125910500.SGD","BK4585","BK4563"],"gpt_icon":0},{"id":"2501884206","title":"Citius Oncology to explore strategic alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501884206","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501884206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:57","pubTimestamp":1736254648,"startTime":"0","endTime":"0","summary":"Citius Oncology , a majority-owned subsidiary of Citius Pharmaceuticals , announced that it has retained Jefferies  as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology’s commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls. Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital. Biotech Alert: Searches spiking for these stocks today. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-oncology-explore-strategic-alternatives-125728286.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-oncology-explore-strategic-alternatives-125728286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTXR","BK4139","BK4007","JEF","BK4127","CTOR"],"gpt_icon":0},{"id":"2501267825","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2501267825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501267825?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:02","pubTimestamp":1736197371,"startTime":"0","endTime":"0","summary":"Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund  easing 0.1%.The iShares Biotechnology ETF  added 0.1%.In corporate news, Predictive Oncology  shares surged past 55% after it agreed to be acquired by Renovaro  in an all-stock deal. Renovaro shares popped 10%.Citius Pharmaceuticals'  majority-owned subsidiary Citius Oncology  said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives. Citius Pharmaceuticals shares were down 2.3% and Citius Oncology jumped 18%.Revance Therapeutics  shares jumped 12%. The company has received a new buyout proposal from Teoxane Laboratories, offering $3.60 per share in cash, topping a bid from Crown Laboratories of $3.10 per share.Regional Health Properties  and SunLink Health Systems  have agreed to merge in an all-stock deal. Regional shares soared 120% and SunLink surged 16%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4585","POAI","BK4588","BK4139","BK4581","CTOR","BK4185","RVNC","IBB","SSY","XLV","RHE","RENB","BK4082","CTXR","LU0053671581.USD","BK4198"],"gpt_icon":0},{"id":"2501234862","title":"Citius Oncology Retains Jeffries to Consider Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501234862","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501234862?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:34","pubTimestamp":1736170468,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals'  majority-owned subsidiary Citius Oncology  said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.Citius Oncology Chief Executive Leonard Mazur said the \"goal is to deliver value to shareholders.\"Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTOR","CTXR","BK4139","BK4007"],"gpt_icon":0},{"id":"2501236187","title":"Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501236187","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501236187?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA99FLMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTXR","BK4007","BK4139","CTOR"],"gpt_icon":0},{"id":"2501968239","title":"Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501968239","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501968239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167800,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc.  , a majority-owned subsidiary of Citius Pharmaceuticals, Inc.  , today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.Citius Oncology is committed to commercializing LYMPHIR, recently approved by the U.S. Food and Drug Administration  for the treatment of patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  following at least one prior systemic therapy.In 2021, denileukin diftitox received regulatory approval in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-oncology-engages-jefferies-exclusive-125000511.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-oncology-engages-jefferies-exclusive-125000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTXR","BK4139","CTOR"],"gpt_icon":0},{"id":"2495354622","title":"Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2495354622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495354622?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:10","pubTimestamp":1735560625,"startTime":"0","endTime":"0","summary":"D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-upgraded-to-buy-from-hold-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-upgraded-to-buy-from-hold-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOR","BK4139","CTXR","BK4007"],"gpt_icon":0},{"id":"2495904325","title":"Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2495904325","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495904325?lang=en_us&edition=fundamental","pubTime":"2024-12-30 16:40","pubTimestamp":1735548043,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 63.16 percent decrease over losses of $(0.19) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42717992/reported-friday-citius-oncology-fy-2024-gaap-eps-0-31-misses-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR"],"gpt_icon":0},{"id":"2494355284","title":"BRIEF-Citius Oncology Reports Fiscal Full Year 2024 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494355284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494355284?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:05","pubTimestamp":1735337140,"startTime":"0","endTime":"0","summary":"Dec 27 (Reuters) - Citius Oncology Inc   :   * CITIUS ONCOLOGY, INC. REPORTS FISCAL FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2494551823","title":"Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494551823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494551823?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:00","pubTimestamp":1735336805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nTUA2HQMV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2494355181","title":"Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494355181","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494355181?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:00","pubTimestamp":1735336800,"startTime":"0","endTime":"0","summary":"Clinical and regulatory success in 2024 expected to drive value in 2025. CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.  , a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024.Fiscal Full Year 2024 Business Highlights and Subsequent Developments. -- Achieved U.S. Food and Drug Administration  approval of LYMPHIR. , an immunotherapy for the treatment of adults. with relapsed or refractory cutaneous T-cell lymphoma ;-- Advanced manufacturing, marketing and sales activities in preparation for. commercial launch of LYMPHIR in the first half of 2025;-- Completed the merger of Citius Pharma's oncology subsidiary with TenX. Keane to form Citius Oncology, Inc., a standalone publicly traded company. which began trading on the Nasdaq exchange under the ticker symbol CTOR. the University of Pittsburgh Medical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4022","BK4099","CTXR","BK4588","BK4585","LDO.USD.HKCC","03160","SITC","BK4080","BK4555","CTOR","R","TM","BK4139","BK4007","BK4232"],"gpt_icon":0},{"id":"2494355129","title":"Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494355129","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494355129?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:00","pubTimestamp":1735336800,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc.  , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024.Fiscal Full Year 2024 Business Highlights and Subsequent Developments. Achieved U.S. Food and Drug Administration  approval of LYMPHIR , an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma ;Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024, following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company;Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included:. Manufactured initial inventory for launch and finalized supply chain ag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-oncology-inc-reports-fiscal-220000506.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-oncology-inc-reports-fiscal-220000506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SITC","CTOR","BK4231","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1748059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2025-06-06","current":-2.671453,"percent":0.748744,"low":-8.240776,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"high":-1.770477,"avg":-3.888279,"sd":1.434871,"marketCap":69405829},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829}],"updateTime":1749375297524}}}